Key points are not available for this paper at this time.
The promise of prostate-specific membrane antigen (PSMA)–targeted radionuclide therapy is being demonstrated by a growing number of reports detailing institutional experience with various agents, and prospective clinical trials are in progress to further establish the safety and efficacy of this
Taïeb et al. (Fri,) studied this question.